An Insight Into the Structure–Activity Relationship Studies of Anticancer Medicinal Attributes of 7-Azaindole Derivatives: A Review

References

• Merour J , BuronF , PléKet al. The azaindole framework in the design of kinase inhibitors. Molecules19(12), 19935–19979 (2014).
   PubMed Web of Science ®Google Scholar
• Sharma N , Anurag. 7-Azaindole Analogues as bioactive agents and recent results. Mini-Rev. Med. Chem.19, 727–736 (2019).
   PubMed Web of Science ®Google Scholar
• Pecoraro C , FrancoMD , CarboneDet al. 1,2,4-Amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: synthesis and pharmacological evaluation. Eur. J. Chem.249, 115134 (2023).
   Web of Science ®Google Scholar
• Motati DR , AmaradhiR , GaneshT. Azaindole therapeutic agents. Bio. Med. Chem.28(24), 115830 (2020).
   PubMed Web of Science ®Google Scholar
• Bettayeb K , TiradoOM , Marionneau-LambotSet al. A new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res.67, 8325–8334 (2007).
   PubMed Web of Science ®Google Scholar
• Kim G , McKeeAE , NingYMet al. FDA Approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin. Cancer Res.20, 4994–5000 (2014).
   PubMed Web of Science ®Google Scholar
• Tap WD , GelderblomH , PalmeriniEet al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet394, 478–487 (2019).
   PubMed Web of Science ®Google Scholar
• Cincinelli R , MussoL , MerliniLet al. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors. Bioorg. Med. Chem.22, 1089–1103 (2014).
   PubMed Web of Science ®Google Scholar
• Hardwicke MA , OleykowskiCA , PlantRet al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol. Cancer Ther.8(7), 1808–1817 (2009).
   PubMed Web of Science ®Google Scholar
• Farmer LJ , LedeboerMW , HoockTet al. Discovery of VX-509 (decernotinib): a potent and selective Janus kinase (JAK) 3 inhibitor for the treatment of autoimmune diseases. J. Med. Chem.58(18), (2015).
   Web of Science ®Google Scholar
• Rekulapally S , JarapulaR , GangarapuKet al. In silico and in vitro studies of novel 7-azaindole and 7-azaisatin derivatives as potent anticancer agents. Med. Chem. Res.24, 3412–3422 (2015).
   Web of Science ®Google Scholar
• Rottmann M , McNamaraC , YeungBKSet al. Spiroindolones, a potent compound class for the treatment of malaria. Science329, 1175–1180 (2010).
   PubMed Web of Science ®Google Scholar
• Vine KL , LockeJM , RansonMet al. An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J. Med. Chem.50, 5109–5117 (2007).
   PubMed Web of Science ®Google Scholar
• Sriram R , SeshasaipavanKumar CN , RaghunandanNet al. AlCl3/PCC-SiO2-promoted oxidation of azaindoles and indoles. Synth. Commun.42, 3419–3428 (2012).
   Web of Science ®Google Scholar
• Hogan M , CotterJ , ClaffeyJet al. Synthesis and cytotoxicity studies of new (dimethylamino)-functionalisedand 7-azaindole-substituted titanocene anticancer agents (7-azaindole¼ 1h-pyrrolo[2,3-b]pyridine). Hel. Chim. Acta.91 (2008).
   Web of Science ®Google Scholar
• Allen OR , CrollL , GottALet al. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics23, 288–292 (2004).
   Web of Science ®Google Scholar
• Causey PW , BairdMC , ColeSPC. Synthesis, characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. Organometallics23, 4486–4494 (2004).
   Web of Science ®Google Scholar
• Kelter G , SweeneyN , StrohfeldtKet al. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anticancer Drugs16, 1091–1098 (2005).
   PubMed Web of Science ®Google Scholar
• Pampillon C , SweeneyN , StrohfeldtK , TackeM. Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. J. Organomet. Chem.692, 2153–2159 (2007).
   Web of Science ®Google Scholar
• Hogan M , ClaffeyJ , PampillonCet al. Synthesis and cytotoxicity studies of new dimethylamino functionalized and azole substituted titanocene anticancer drugs. Organometallics26, 2501–2506 (2007).
   Web of Science ®Google Scholar
• Krishna AMS , GandhamHB , ValluruKRet al. Design, synthesis and anticancer activity of arylketo alkyne derivatives of 7-azaindole-oxazole. Chem. Data Collect.34, 100743 (2021).
   Google Scholar
• Routier S , PeixotoP , MerourJYet al. Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents. J. Med. Chem.48, 1401–1413 (2005).
   PubMedGoogle Scholar
• Kim Y , HongMS. Identification of lead small molecule inhibitors of glycogen synthase kinase-3 beta using a fragment-linking strategy. Bioorg. Med. Chem. Lett.26, 5669–5673 (2016).
   PubMed Web of Science ®Google Scholar
• Liu B , YuanX , XuBet al. Synthesis of novel 7-azaindole derivatives containing pyridin-3- ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors. Eur. J. Med. Chem.170, 10–15 (2019).
   Web of Science ®Google Scholar
• Chaneton B , GottliebE. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci.37, 309–316 (2012).
   PubMed Web of Science ®Google Scholar
• Gao X , WangH , YangJJet al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell45, 598–609 (2012).
   PubMed Web of Science ®Google Scholar
• Luo W , HuH , ChangRet al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell145, 732–744 (2011).
   PubMed Web of Science ®Google Scholar
• Mazurek S . Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol.43, 969–980 (2011).
   PubMed Web of Science ®Google Scholar
• Morgan HP , O’ReillyFJ , WearMAet al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc. Natl. Acad. Sci. Unit. States Am.110, 5881–5886 (2013).
   PubMed Web of Science ®Google Scholar
• Hitosugi T , KangS , Vander HeidenMGet al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal.2, 1–10 (2009).
   Web of Science ®Google Scholar
• Yang W , XiaY , HawkeDet al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell150, 685–696 (2012).
   PubMed Web of Science ®Google Scholar
• Christofk HR , Vander HeidenMG , HarrisMHet al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature452, 230–233 (2008).
   PubMed Web of Science ®Google Scholar
• Chaneton B , HillmannP , ZhengLet al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature491, 458–462 (2012).
   PubMed Web of Science ®Google Scholar
• Israelsen WJ , Vander HeidenMG. Pyruvate kinase: function, regulation and role in cancer. Semin. Cell Dev. Biol.43, 43–51 (2015).
   PubMed Web of Science ®Google Scholar
• Mazurek S , BoschekCB , HugoF , EigenbrodtE. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Canc. Biol.15, 300–308 (2005).
   PubMed Web of Science ®Google Scholar
• Warner SL , CarpenterKJ , BearssDJ. Activators of PKM2 in cancer metabolism. Future Med. Chem.06, 1167–1178 (2014).
   Google Scholar
• Wahlberg E , KarlbergT , KouznetsovaEet al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. J. Nat. Biotechnol.30(3), 283–288 (2012).
   PubMed Web of Science ®Google Scholar
• Javle M , CurtinN. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer105(8), 1114–1122 (2011).
   PubMed Web of Science ®Google Scholar
• De Vos M , SchreiberV , DantzerF. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol.84(2), 137–146 (2012).
   PubMed Web of Science ®Google Scholar
• Powell C , MikropoulosC , KayeSBet al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radio sensitisers. J. Cancer Treat. Rev.36(7), 566–575 (2010).
   PubMed Web of Science ®Google Scholar
• Farmer H , McCabeN , LordCJet al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434, 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Bryant HE , SchultzN , ThomasHDet al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature434, 913–917 (2005).
   PubMed Web of Science ®Google Scholar
• Maxwell KN , DomchekSM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat. Rev. Clin. Oncol.9, 520–528 (2012).
   PubMed Web of Science ®Google Scholar
• Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol.5(4), 387–393 (2011).
   PubMed Web of Science ®Google Scholar
• Welsby I , HutinD , LeoO. Complex roles of members of the ADP-ribosyl transferase super family in immune defences: looking beyond PARP1. Biochem. Pharmacol.84, 11–20 (2012).
   PubMed Web of Science ®Google Scholar
• Swindall AF , StanleyJA , YangES. PARP-1: friend or foe of DNA damage and repair in tumorigenesis?Cancers5(3), 943–958 (2013).
   PubMedGoogle Scholar
• Ma Y , ChenH , HeXet al. NAD+ metabolism and NAD+-dependent enzymes: promising therapeutic targets for neurological diseases. Curr. Drug Targets13(2), 222–229 (2012).
   PubMed Web of Science ®Google Scholar
• Ferraris DV . Evolution of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem.53(12), 4561–4584 (2010).
   PubMed Web of Science ®Google Scholar
• Peng Z , DayunS , HualiXet al. Synthesis and antitumor activity of a new 7-azaindole derivative. Chem. Res. Chin. Univ.30(3), 420–424 (2014).
   Web of Science ®Google Scholar
• Jose R , VenancioR , Concepcionde Het al. New 7-azaindole palladium and platinum complexes: crystal structures and theoretical calculations. In vitro anticancer activity of the platinum compounds. Dalton Trans.39(13), 3290–3301 (2010).
   PubMed Web of Science ®Google Scholar
• Wang T , WallaceOB , ZhangZXet al. US6632819 (2003).
   Google Scholar
• Walker SR , CarterEJ , HuffBC , MorrisJ. Variolins and related alkaloids. Chem. Rev.109, 3080 (2009).
   PubMed Web of Science ®Google Scholar
• Hong S , LeeS , KimBet al. Discovery of new azaindole-based PI3Kα inhibitors: apoptotic and antiangiogenic effect on cancer cells. Bioorg. Med.Chem. Lett.20, 7212 (2010).
   PubMed Web of Science ®Google Scholar
• Hugon B , AnizonF , BaillyCet al. Synthesis and biological activities of isogranulatimide analogues. Bioorg. Med. Chem.15, 5965–5980 (2007).
   PubMed Web of Science ®Google Scholar
• Dayde-Cazals B , FauvelB , SingerMet al. Rational design, synthesis, and biological evaluation of 7-azaindole derivatives as potent focused multi-targeted kinase inhibitors. J. Med. Chem.59, 3886–3905 (2016).
   PubMed Web of Science ®Google Scholar
• Gerlinger M , RowanAJ , HorswellSet al. Intratom or heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med.366(10), 883–892 (2012).
   PubMed Web of Science ®Google Scholar
• Klein CA . Selection and adaptation during metastatic cancer progression. Nature501(7467), 365–372 (2013).
   PubMed Web of Science ®Google Scholar
• Gossage L , EisenT. Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res.16(7), 1973–1978 (2010).
   PubMed Web of Science ®Google Scholar
• Knight ZA , LinH , ShokatKM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer10(2), 130–137 (2010).
   PubMed Web of Science ®Google Scholar
• Cheve G , BoriesC , FauvelBet al. De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases. Med. Chem. Comm.3(7), 788–800 (2012).
   Google Scholar
• Fauvel B , Coisy-QuivyM , VivierSet al. Anti-tumor activity of novel compounds targeting BCR-ABL, c-SRC and BCR-ABLT315I in chronic myelogenous leukemia. Am. J. Cancer Sci.2(1), 28–36 (2013).
   Google Scholar
• Gorecki L , MuthnaD , MerditaSet al. 7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties. Eur. J. Med. Chem.240, 114580 (2022).
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TMA , MiddletonFK , AroraAet al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol. Oncol.9, 569–585 (2015).
   PubMed Web of Science ®Google Scholar
• Cleary JM , AguirreAJ , ShapiroGI , D’AndreaAD. Biomarker-guided development of DNA repair inhibitors. Mol. Cell.78, 1070–1085 (2020).
   PubMed Web of Science ®Google Scholar
• Massague J . G1 cell-cycle control and cancer. Nature432, 298–306 (2004).
   PubMed Web of Science ®Google Scholar
• Blackford AN , JacksonSP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell.66, 801–817 (2017).
   PubMed Web of Science ®Google Scholar
• Saldivar JC , CortezD , CimprichKA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol.18, 622–636 (2017).
   PubMed Web of Science ®Google Scholar
• Krajewska M , FehrmannRSN , SchoonenPMet al. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene34, 3474–3481 (2015).
   PubMed Web of Science ®Google Scholar
• Prevo R , FokasE , ReaperPMet al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther.13, 1072–1081 (2012).
   PubMed Web of Science ®Google Scholar
• Gorecki L , AndrsM , RezacovaM , KorabecnyJ. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol. Ther.107518 (2020).
   PubMed Web of Science ®Google Scholar
• Knegtel R , CharrierJD , DurrantSet al. Rational design of 5-(4- (Isopropylsulfonyl) phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl) pyrazin-2-amine (VX-970, M6620): optimization of intra- and intermolecular polar interactions of a new ataxia telangiectasia mutated and Rad3-related (ATR) kinase inhibitor. J. Med. Chem.62, 5547–5561 (2019).
   PubMed Web of Science ®Google Scholar
• Charrier JD , DurrantSJ , GolecJMCet al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem.54, 2320–2330 (2011).
   PubMed Web of Science ®Google Scholar
• Plietker MW , MerkulE , EsdarCet al. Discovery of novel 7-azaindoles as PDK1 inhibitors. Bioorg. Med. Chem. Lett.26(13), 3073–3080 (2016).
   PubMed Web of Science ®Google Scholar
• Carbone D , VestutoV , RosaliaMet al. Ferraro Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification. Eur. J. Med. Chem.234, 114233 (2022).
   PubMed Web of Science ®Google Scholar
• Feneyrolles C , GuietL , SingerMet al. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors. Bio. Med. Chem. Lett.27(4), 862–866 (2017).
   PubMed Web of Science ®Google Scholar
• Corno C , GattiL , LanziCet al. Role of the receptor tyrosine kinase Axl and its targeting in cancer cells. Curr. Med. Chem.23, 1496 (2016).
   PubMed Web of Science ®Google Scholar
• Feneyrolles C , SpenlinhauerA , GuietLet al. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol. Cancer Ther.13, 2141–2148 (2014).
   PubMed Web of Science ®Google Scholar
• Hong S , KimJ , SeoJH , JungKH , HongSS. Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities. J. Med. Chem.55, 5337–5349 (2012).
   PubMed Web of Science ®Google Scholar